+------------------------------------------------------------------------------+
BFW 02/12 07:06 Reckitt 4Q LFL Sales Growth Ex-RBP +4%, In Line With Ests.
+------------------------------------------------------------------------------+
Reckitt 2Q LFL Sales Growth Matches Est., to Demerge RB Pharma 2014-07-28 06:05:53.619 GMT
By Chiara Remondini July 28 (Bloomberg) -- Reckitt Benckiser 2Q like-for-like sales ex-pharma (RBP) +4%, vs est. 4% (median of 7 ests). * 1H net rev. GBP4.67b, est. GBP4.69b * 1H adj. net income GBP829m, est. GBP804m * Interim div. 60p/shr, in line with BDVD forecast * Says on track to achieve full-yr total revenue growth target at constant FX, excl. RBP, of 4%-5% * Says mkt conditions will remain challenging in 2H, particularly in U.S., certain emerging markets * Says to pursue demerger of RB Pharmaceuticals with separate U.K. listing, expects this to take place in next 12 months * NOTE outlook 2014 (April 16): net revenue growth of 4%-5% at constant rates, “flat to moderate” operating margin expansion adjusted to exclude impact of exceptional items (both targets exclude RBP) * Statement * Preview
For Related News and Information: First Word scrolling panel: FIRST<GO> First Word newswire: NH BFW<GO>
To contact the reporter on this story: Chiara Remondini in Milan at +39-02-8064-4241 or cremondini@bloomberg.net To contact the editors responsible for this story: James Ludden at +44-20-7673-2645 or jludden@bloomberg.net Stefania Spezzati